Impact of respiratory syncytial virus infection and palivizumab on severe acute lower respiratory infection during the first 6 months of life in a cohort of Colombian infants. Source: International Congress 2018 – Clinical problems in paediatric pulmonology Year: 2018
Palivizumab prophylaxis, respiratory syncytial virus and subsequent recurrent wheezing: a 2-year follow-up study Source: Eur Respir J 2006; 28: Suppl. 50, 758s Year: 2006
Respiratory syncytial virus infection in childcare and hospitalized children with different respiratory disease severity Source: Annual Congress 2006 - Virus-induced respiratory tract infection Year: 2006
RSV and human metapneumovirus – major pathogens of childhood – also adults and the elderly? Source: Annual Congress 2005 - Major viral threats to the lung Year: 2005
Premorbid lung function, respiratory syncytial virus infection and chronic respiratory morbidity in prematurely born infants Source: Annual Congress 2005 - Pulmonary function outcome, respiratory morbidity in prematurely born children and acute lung injury Year: 2005
Influenza- and respiratory syncytial virus-associated mortality and hospitalisations Source: Eur Respir J 2007; 30: 1158-1166 Year: 2007
Rhinovirus infections in infants: is respiratory syncytial virus ready for the challenge? Source: Eur Respir J 2008; 32: 249-251 Year: 2008
Short-term survival of acute respiratory distress syndrome patients due to influenza virus infection alone: a cohort study Source: ERJ Open Res, 6 (4) 00587-2020; 10.1183/23120541.00587-2020 Year: 2020
Respiratory syncytial virus (RSV) prophylaxis in special populations Source: Annual Congress 2011 - Paediatric epidemiology: bronchiolitis, pneumonia, asthma and spirometry in non-respiratory conditions Year: 2011
Decreased lung function precedes severe respiratory syncytial virus infection and post-respiratory syncytial virus wheeze in term infants Source: Eur Respir J 2014; 44: 666-674 Year: 2014
Prevalence of respiratory syncytial virus (RSV) hospitalisation, and subsequent airway symptoms in late preterm infants Source: Annual Congress 2008 - Paediatric respiratory epidemiology II: air pollution studies and infectious disease epidemiology Year: 2008
Prophylaxis against respiratory syncytial virus in high-risk infants Source: Eur Respir Monogr 2021; 92: 361-371 Year: 2021
Oral presentation: The long-term effect of neonatal respiratory syncytial virus (RSV) infection on the response to adult allergen challenge Source: Lung Science Conference 2013 - Early origins and mechanisms of chronic lung disease Year: 2013
Respiratory syncitial virus infection in hospitalized Brazilian infants with acute lower respiratory disease: incidence and associated factors Source: Eur Respir J 2005; 26: Suppl. 49, 628s Year: 2005
Respiratory syncytial virus: the role of specific serum antibodies in hospitalized infants with lower respiratory disease Source: Eur Respir J 2005; 26: Suppl. 49, 27s Year: 2005
Incidence of respiratory syncytial virus (RSV) positivity in young Italian children referred to the emergency departments for lower respiratory tract infection (LRTI) over two consecutive epidemic seasons Source: Eur Respir J 2004; 24: Suppl. 48, 622s Year: 2004
Efficacy and safety of palivizumab in preterm infants 29-32 weeks gestational age without chronic lung disease to prevent serious respiratory syncytial virus respiratory tract infection Source: Eur Respir J 2002; 20: Suppl. 38, 531s Year: 2002
Respiratory syncytial virus: still a global burden for children Source: Breathe 2010; 7: 96 Year: 2010
Prospective study on the contribution of respiratory syncytial virus (RSV) to acute lower respiratory tract infections (ALRTI) in young hospitalised children Source: Eur Respir J 2004; 24: Suppl. 48, 622s Year: 2004
Respiratory syncytial virus: types and genotypes of the virus in infants hospitalized with lower respiratory tract infection in Brazil Source: Eur Respir J 2005; 26: Suppl. 49, 27s Year: 2005